OverviewSuggest Edit

XOMA is a biotechnology company discovering, developing and commercializing antibody-based therapeutics. The Company’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia.
TypePublic
Founded1981
HQEmeryville, CA, US
Websitexoma.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Nov 2019)10(-9%)
Revenue (FY, 2020)$29.4 M(+60%)
Share Price (Oct 2021)$25.8(+2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at XOMA

James R. Neal

James R. Neal

Chief Executive Officer and Member of the Board of Directors
Joseph M. Limber

Joseph M. Limber

Director
Natasha Hernday

Natasha Hernday

Director
Tom Burns

Tom Burns

Senior Vice President, Finance and Chief Financial Officer
Matthew Perry

Matthew Perry

Director
Jack L. Wyszomierski

Jack L. Wyszomierski

Director
Show more

XOMA Office Locations

XOMA has an office in Emeryville
Emeryville, CA, US (HQ)
2200 Powell St #310
Show all (2)

XOMA Financials and Metrics

XOMA Revenue

XOMA's revenue was reported to be $29.39 m in FY, 2020
USD

Revenue (Q1, 2021)

375.0k

Net income (Q1, 2021)

(7.4m)

EBIT (Q1, 2021)

(6.4m)

Market capitalization (15-Oct-2021)

290.6m

Closing stock price (15-Oct-2021)

25.8

Cash (31-Mar-2021)

67.8m

EV

242.1m
XOMA's current market capitalization is $290.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

58.2m33.8m35.5m18.9m55.4m5.6m52.7m5.3m18.4m29.4m

Cost of goods sold

143.0k

Gross profit

33.6m

Gross profit Margin, %

100%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

16.5m16.2m9.9m9.3m7.3m9.5m7.2m6.3m3.4m6.0m5.1m2.7m2.5m2.1m4.0m443.0k635.0k260.0k10.9m36.2m463.0k2.3m896.0k8.1m962.0k8.9m804.0k444.0k557.0k375.0k

Cost of goods sold

81.0k28.0k46.0k21.0k

Gross profit

9.2m7.2m9.4m7.1m

Gross profit Margin, %

99%100%100%100%
USDQ2, 2011

Financial Leverage

3.3 x
Show all financial metrics

XOMA Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

XOMA Online and Social Media Presence

Embed Graph

XOMA News and Updates

NEXE Adds Three New Products to the XOMA Superfoods Line

VANCOUVER, BC, Oct. 14, 2021 /PRNewswire/ - NEXE Innovations Inc. ("NEXE" or the "Company"), (TSXV: NEXE) (OTC Markets: NEXNF) (Frankfurt: NX5), a leader in plant-based materials manufacturing, is pleased to announce the addition of three new beverages to its XOMA Superfoods line...

XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)’s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021, at 10:20 AM PT.

XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events

Added six assets to its portfolio of potential milestone and royalty assets in 2021

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Ad hoc announcement pursuant to Article 53 of the SIX listing rules

XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences

EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals’ vidutolimod (CMP-001), an advanced-generation Toll-like receptor 9 agonist packaged in a virus-…

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock:
Show more

XOMA Blogs

XOMA Purchases Commercial Payment Rights to BLA-Review-Stage Asset

Today we announced an important transaction for XOMA. We purchased the rights to a 0.5% commercial payment stream in a BLA-review-stage asset – faricimab – for a $6 million upfront plus potential future milestone payments. Faricimab currently is under Priority Review by the U.S. Food and Drug Admini…

XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference held on September 13-15, 2021.  The presentation will be available on d…

XOMA Announces Heather L. Franklin Joins its Board of Directors

EMERYVILLE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined the Company’s Board of Directors. Ms. Franklin has significant experience in corporate development …

XOMA: The royalty aggregator that thinks like a biotech

By Guy Martin For biotech companies, the prospect of receiving non-dilutive, non-recourse funding to advance their assets even through the early stages of clinical development may sound too good to be true. But that is exactly what is offered by XOMA (Nasdaq: XOMA), a unique company that started to …

XOMA Prices $35 Million Offering of Depositary Shares

Depositary shares represent an interest in 8.375% Series B Cumulative Perpetual Preferred Stock EMERYVILLE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 1,400,000 …

XOMA Announces Offering of Depositary Shares and Series B Cumulative Perpetual Preferred Stock

EMERYVILLE, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of depositary shares, each representing 1/1000th fractional interest in a share of the Company’s Series B Cum…
Show more

XOMA Frequently Asked Questions

  • When was XOMA founded?

    XOMA was founded in 1981.

  • Who are XOMA key executives?

    XOMA's key executives are James R. Neal, Joseph M. Limber and Natasha Hernday.

  • How many employees does XOMA have?

    XOMA has 10 employees.

  • What is XOMA revenue?

    Latest XOMA annual revenue is $29.4 m.

  • What is XOMA revenue per employee?

    Latest XOMA revenue per employee is $2.9 m.

  • Who are XOMA competitors?

    Competitors of XOMA include Humanigen, Hutchison China Meditech and Pfizer.

  • Where is XOMA headquarters?

    XOMA headquarters is located at 2200 Powell St #310, Emeryville.

  • Where are XOMA offices?

    XOMA has an office in Emeryville.

  • How many offices does XOMA have?

    XOMA has 2 offices.